人类免疫缺陷病毒和丙型肝炎病毒合并感染患者的抗病毒治疗进展  

Antiviral therapy progress in human immunodeficiency virus and hepatitis C virus co-infected patients

作　　者：孙洪清[1] 黄琴[1] 徐国光[2] 蔡卫平 胡芸文[4] 

机构地区：[1]上海市公共卫生临床中心感染科,上海200083 [2]上海市公共卫生临床中心肝病科,上海200083 [3]广州第八人民医院感染科,广东广州510060 [4]上海市公共卫生临床中心检验科,上海200083

出　　处：《中国新药与临床杂志》2013年第5期343-346,共4页Chinese Journal of New Drugs and Clinical Remedies

基　　金：卫生部艾滋病防治研究项目(WA-2007-05);国家科技重大专项项目(2008ZX10001-008)

摘　　要：目前对人类免疫缺陷病毒(HIV)和丙型肝炎病毒(HCV)合并感染的患者抗病毒治疗争议颇多。有些学者认为两种病毒相互作用加速了疾病进程,有些学者则认为因合并感染引起了肝脏、肾脏、心脏等方面的问题,所以对抗HIV和抗HCV的治疗方案必须要重新考虑新的策略。最近有些学者的研究结果显示早治疗可以降低发病率和病死率,并且认为对合并感染的患者选择个体化的治疗可以降低不良反应。本文综述抗病毒治疗的必要性、最佳时机和最佳方案。There are many controversies about antiviral therapy on human immunodeficiency virus （HIV） / hepatitis C virus （HCV） co- infection patients. Some scholars consider that the interaction of two viruses accelerates the disease process. Other scholars think that we should reconsider a new therapeutic strategy to combat HIV/HCV co-infection, because of which cause the problems related to liver, kidney, heart and so on. Recently, some scholars study results show that early treatment can reduce morbidity and mortality. And co- infected patients select individualized treatment can reduce the adverse reactions. The necessary, the best opportunity and scheme of antiviral therapy are summarized in this text.

关 键 词：HIV 肝炎病毒 药物疗法 

分 类 号：R978.7[医药卫生—药品]